Evidence map›Paper›PMID 40002243›Full record

ArticleCancers2025

NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts' Study.

Alessandra Buja, Massimo Rugge, Alberto Bortolami, Manuel Zorzi, Federico Rea, Anna Zanovello, Giovanna Scroccaro, Pierfranco Conte, Giulia Pasello, Valentina Guarneri and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Alessandra BujaDepartment of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padova, Via Loredan, 18, 35100 Padova, Italy.ORCID 0000-0003-2216-3807
Massimo RuggeDepartment of Medicine DIMED-Pathology Unit University of Padova, 35100 Padova, Italy.
Alberto BortolamiCoordinamento Regionale per le Attività Oncologiche (CRAO), Regione Veneto, 30100 Venezia, Italy.
Manuel ZorziVeneto Tumor Registry (RTV), Azienda Zero, 35100 Padova, Italy.ORCID 0000-0001-6025-5214
Federico ReaDepartment of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padova, Via Loredan, 18, 35100 Padova, Italy.
Anna ZanovelloDepartment of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padova, Via Loredan, 18, 35100 Padova, Italy.ORCID 0009-0009-4627-0843
Giovanna ScroccaroCoordinamento Regionale per le Attività Oncologiche (CRAO), Regione Veneto, 30100 Venezia, Italy.
Pierfranco ConteCamillo Hospital IRCCS, Regione Veneto, 30100 Venezia, Italy.ORCID 0000-0002-5210-5344
Giulia PaselloOncologia Medica 2, Istituto Oncologico Veneto, I.R.C.C.S., 35100 Padova, Italy.
Valentina GuarneriOncologia Medica 2, Istituto Oncologico Veneto, I.R.C.C.S., 35100 Padova, Italy.ORCID 0000-0002-2375-8397
On Behalf Of Rete Oncologica Veneta
Periplo Foundation

Funding

Periplo foundation xxx
6 · The paper itself

Abstract

introductionThis retrospective follow-up study evaluates patient outcomes and treatment costs in two cohorts of incident NSCLC patients recorded in the population-based cancer registry of the Veneto Region in 2017 and 2019.

methodsThis study examines two cohorts of incident NSCLC patients recorded by the Regional Veneto cancer registry in 2017 (493 patients) and 2019 (557 patients). Cancer patients were followed for three years after diagnosis to assess the disease's outcomes and analyze the overall treatment-related costs. Overall survival and cancer-specific mortality were evaluated using Cox regression models. The log-transformed overall treatment costs for the 3 years following diagnosis were analyzed using linear regression.

resultsThe overall mortality risk significantly lowered in the 2019 cohort (HR 0.84; 95% CI 0.72-0.98,

conclusionsThese results revealed notable differences in clinical outcomes and patient-related costs in incident NSCLCs in 2017 and 2019. The study highlights the importance of monitoring clinical outcomes and management costs in real-world oncology practice.

Indexed as

health care costshealth economicslung cancerNSCLCpopulation-based studiesreal-world oncology

Identifiers

PMID40002243
PMCPMC11853645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.